International Alliance of Patients' Organizations

Printer-friendly version
Meeting: 
Seventy-second World Health Assembly (A72/1)
Agenda Item: 
- Prevention and control of noncommunicable diseases
Statement: 

The International Alliance of Patients’ Organizations (IAPO) is an alliance of patient groups in official relationship with the WHO and representing the interests of patients worldwide. We have over 270 member organizations based in over 70 countries covering over 50 different disease areas.

We welcome the Director General’s Report A72/19 and welcome that even more patients will be covered by the broadened scope of the commitments of the “4 x 4 NCD agenda” with the inclusion of commitments to reduce air pollution and promote mental health and well-being within the “5 x 5 NCD agenda”.

IAPO wants Member States to integrate the health and wellbeing of patients already diagnosed with NCDs within their scaled up multi-stakeholder and multisectoral responses for the prevention and control of NCDs in the context of the 2030 Agenda for Sustainable Development. Member States must include secondary prevention programmes to address the needs of these patients within their “NCD accelerators”.

Secondary prevention interventions should form a part of the overall WHO list of ‘best buys’ and other recommended interventions for the prevention and control of NCDs. We note that we already have a list of NCD secondary prevention ‘best buys’ for low and middle-income countries in the WHO Report Secondary prevention of NCDs in low- and middle-income countries through community-based and health service interventions (WHO and Wellcome Trust 2001).

We endorse the Director General’s Report A72/19 sections 12-24 and welcome that the Secretariat is developing a delivery plan to meet the rapidly increasing demand for technical assistance requested by Member States and for ensuring optimal delivery of the WHO’s 13th General Programme of Work, 2019–2023.

The Health Assembly is invited to note the report and to adopt the draft decision recommended by the Executive Board in decision EB144(1).
Thank you for your attention.